Sigilon Therapeutics, Inc. Uncategorized Contracts & Agreements

Form of Contingent Value Right Agreement, by and among Eli Lilly and Company and a rights agent selected by Eli Lilly and Company and reasonably acceptable to Sigilon... (Filed With SEC on June 29, 2023)

Offer Letter, between Sigilon Therapeutics, Inc. and Josias Pontes, dated October 23, 2019 (Filed With SEC on March 14, 2023)

Offer Letter, between Sigilon Therapeutics, Inc. and Sarah Yuan, dated January 12, 2022 (Filed With SEC on March 14, 2023)

Letter Agreement, dated February 10, 2023, between the Company and May Orfali, M.D (Filed With SEC on March 14, 2023)

Letter Agreement, dated August 4, 2021, between the Company and Deya Corzo, M.D (Filed With SEC on March 14, 2022)

Offer Letter, between Sigilon Therapeutics, Inc. and May Orfali, M.D. dated October 27, 2021 (Filed With SEC on March 14, 2022)

Offer Letter, between Sigilon Therapeutics, Inc. and Philip Ashton-Rickardt, dated May 25, 2021 (Filed With SEC on March 14, 2022)

Offer Letter, between Sigilon Therapeutics, Inc. and Deya Corzo, M.D. dated September 26, 2018 (Filed With SEC on March 14, 2022)

Description of Registered Securities (Filed With SEC on March 18, 2021)

Offer Letter, between Sigilon Therapeutics, Inc. and Rogerio Vivaldi Coelho, M.D., dated April 23, 2018 (Filed With SEC on November 13, 2020)

Offer Letter, between Sigilon Therapeutics, Inc. and Glenn Reicin, dated May 8, 2019 (Filed With SEC on November 13, 2020)

Offer Letter, between Sigilon, Inc. and Devyn Smith, dated March 25, 2017 (Filed With SEC on November 13, 2020)